Piper Sandler on Roivant Sciences (ROIV): 'Mosliciguat Ph2 PHocus Takes Center Stage & Catalyst-Rich 2026'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $40.00 price target on Roivant Sciences (NASDAQ: ROIV).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


